Novel cell therapy treatments offer promise to immune-compromised children
Without this therapy, estimates suggest that less than 30% of patients would recover, using standard protocols.
- Without this therapy, estimates suggest that less than 30% of patients would recover, using standard protocols.
- , the paper’s first author and the Translational Research Laboratory director at the Children’s National Cell Enhancement and Technologies for Immunotherapy (CETI) program.
- They combined the expertise at Children’s National in producing and banking cell therapy products with the community built around the PTCTC.
- In the decade ahead, Dr. Bollard sees promise in cell therapies for patients with cancer, immune deficiencies after transplant and dozens of other disorders, including genetic and autoimmune diseases.